3-ethyl-3-methoxyazetidine hydrochloride | 942307-86-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: 3-ethyl-3-methoxyazetidine hydrochloride
• 英文别名: 3-ethyl-3-methoxyazetidine;hydrochloride
• CAS: 942307-86-0
• 化学式: C₆H₁₃NO*ClH
• 分子量: 151.636
• InChiKey: QAYOJFYHLXVXJI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.81
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-ethyl-3-methoxyazetidine hydrochloride 、 trans-4-[1-(tert-butoxycarbonyl)-4-oxo-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid ethyl ester 在 盐酸 、 三乙酰氧基硼氢化钠 作用下， 以 1,4-二氧六环 、 1,2-二氯乙烷 为溶剂， 反应 96.25h， 生成 trans-4-[(4S)-(3-ethyl-3-methoxyazetidin-1-yl)-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid ethyl ester hydrochloride
  参考文献：
  名称：

  VLA-4 INHIBITORY DRUG

  摘要：

  公开号：

  EP1961750B1
• 作为产物：
  描述：

  tert-butyl 3-ethyl-3-methoxyazetidine-1-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 72.0h， 生成 3-ethyl-3-methoxyazetidine hydrochloride
  参考文献：
  名称：

  VLA-4 INHIBITORY DRUG

  摘要：

  公开号：

  EP1961750B1

文献信息

• [EN] N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS<br/>[FR] DÉRIVÉS DE N2-PHÉNYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE ET LEUR UTILISATION COMME INHIBITEURS DE MPS1
  申请人：CANCER REC TECH LTD

  公开号：WO2015128676A1

  公开（公告）日：2015-09-03

  The present invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1 –also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

  本发明涉及式（I）的化合物，其中R1、R2、R3和R4均如本文所定义。本发明的化合物已知能够通过直接或间接与Mps1激酶本身相互作用来抑制单丝粒体1（Mps1，也称为TTK）激酶的纺锤体检查点功能。具体地，本发明涉及将这些化合物用作治疗和/或预防增殖性疾病，如癌症的治疗剂。本发明还涉及制备这些化合物的方法，以及包含它们的药物组合物。
• VLA-4 inhibitory drug
  申请人：Machinaga Nobuo

  公开号：US20130065882A1

  公开（公告）日：2013-03-14

  This invention relates to a VLA-4 inhibitory drug, having good oral absorbability and exhibiting sufficient anti-inflammatory effects when administered orally, wherein an active ingredient is represented by formula (I), or a salt thereof: Q represents an optionally-substituted monocyclic or bicyclic nitrogen-containing heterocyclic group having a nitrogen atom as the bonding site; Y represents an oxygen atom or CH 2 ; W represents an optionally-substituted bicyclic aromatic hydrocarbon ring group or an optionally-substituted bicyclic aromatic heterocyclic group; A 1 represents a nitrogen atom or C—R 3d wherein R 3d represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group; R 1 represents H or a C1-8 alkyl group; R 2 represents H, a halogen, a C1-8 alkoxy

  本发明涉及一种VLA-4抑制剂药物，具有良好的口服吸收性，并在口服给药时展现足够的抗炎效果，其中活性成分由公式（I）或其盐表示： Q代表一个可选取代的含氮杂环基团，其为单环或双环结构，其中氮原子为键合位点； Y代表一个氧原子或CH2； W代表一个可选取代的双环芳香烃环基团或可选取代的双环芳香杂环基团； A1代表一个氮原子或C-R3d，其中R3d代表氢原子、卤素原子、C1-8烷氧基团或C1-8烷基团； R1代表氢原子或C1-8烷基团； R2代表氢原子、卤素原子、C1-8烷氧基团或C1-8烷基团。
• N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors
  申请人：Cancer Research Technology Limited

  公开号：US10399974B2

  公开（公告）日：2019-09-03

  The present invention relates to compounds of formula I: wherein R1, R2, R3 and R4 are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

  本发明涉及式 I 的化合物： 其中 R1、R2、R3 和 R4 均如本文所定义。已知本发明的化合物可直接或间接通过与 Mps1 激酶本身的相互作用抑制 Monospindle 1（Mps1--又称 TTK）激酶的纺锤体检查点功能。特别是，本发明涉及将这些化合物用作治疗和/或预防癌症等增殖性疾病的治疗剂。本发明还涉及这些化合物的制备工艺以及包含这些化合物的药物组合物。
• N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS
  申请人：Cancer Research Technology Ltd

  公开号：EP3110816A1

  公开（公告）日：2017-01-04
• N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS
  申请人：CANCER RESEARCH TECHNOLOGY LIMITED

  公开号：US20160362409A1

  公开（公告）日：2016-12-15

  The present invention relates to compounds of formula I: wherein R 1 , R 2 , R 3 and R 4 are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.